Gita Ramjee, PhD, known for her extensive work in HIV prevention and a valued colleague to so many in the HIV Vaccine and Prevention Trials Networks (HVTN and HPTN), sadly succumbed to complications associated with SARS-CoV-2 infection (COVID-19) earlier this week.
Gita was a study principal investigator and unit director for many of the National Institutes of Allergy and Infectious Diseases and the Division of AIDS’ HIV prevention networks clinical trials, ranging from early phase studies to late phase efficacy trials. She contributed to the understanding of the role of topical and systemic products in HIV prevention, and more recently, made a notable contribution to the active and passive immunization programs in the HVTN and HPTN.
She will be sorely missed by generations of HIV prevention scientists. Gita’s energy and dynamism were incomparable. Her steadfast commitment to the quest for effective HIV prevention methods and to women’s health will continue to motivate all of us who had the opportunity to know her and work with her.
- Dr. Wafaa El-Sadr, Director of ICAP at Columbia University and Principal Investigator of the HPTN.